Emerging agents for the treatment of metastatic urothelial cancer

Over the past few decades, platinum-based combination chemotherapy (PBCC) has been the preferred initial therapy for metastatic urothelial cancer (mUC). However, despite a response rate of approximately 50%, a small proportion of patients with distant metastases may be cured by cisplatin-based combi...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Whi-An Kwon, Ho Kyung Seo
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Korean Urological Association 2021-05-01
Sraith:Investigative and Clinical Urology
Ábhair:
Rochtain ar líne:https://www.icurology.org/pdf/10.4111/icu.20200597